Alnylam (ALNY) Q4 FY24 earnings call

Alnylam delivered robust commercial and financial performance in Q4 FY24, achieving its first full year of non-GAAP operating profitability. The company is poised for a landmark 2025, driven by the anticipated approval and launch of AMVUTTRA for ATTR cardiomyopathy, which is expected to accelerate TTR franchise growth. Strategic investments in a deep R&D pipeline, including next-generation TTR assets and new Phase I programs, underpin long-term value creation, despite expected near-term gross margin compression.